PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

MD Anderson Research Highlights for October 4, 2023

Featuring progress for peripheral neuropathy and chemobrain, a CAR T cell atlas, a therapeutic target for AML, and risk prediction tools for pancreatic and bone cancer

2023-10-04
(Press-News.org) HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.  

Read this press release in the MD Anderson Newsroom.

Computer game improves chemotherapy-induced peripheral neuropathy symptoms in breast cancer survivors
Chemotherapy-induced peripheral neuropathy (CIPN) causes negative sensations, such as numbness, loss of feeling and pain, for many cancer survivors and remains a major chronic problem after cancer treatment. In a new study, researchers determined working directly with the brain improves the perception of neuropathy. This study, led by Sarah Prinsloo, Ph.D., divided 91 breast cancer survivors experiencing CIPN into three groups. One group participated in sessions with a closed-loop brain-computer interface (BCI), a second group received placebo feedback, and a third group received no intervention. During each session, trial participants played a computer game designed to change the way the brain processed sensations and movements. After 20 sessions, only the two intervention groups experienced significant symptom reduction. The BCI group experienced the largest improvements, and their symptoms continued to improve for one month after their last session, while the placebo group’s symptoms returned. Learn more in Cancer.

Single-cell atlas of CD19 CAR T cells provides a public resource to drive insights into B cell lymphoma
Many patients with relapsed/refractory (R/R) large B cell lymphoma respond well to chimeric antigen receptor (CAR) T cell therapy targeting CD19, but the majority do not have a durable response, highlighting a need to understand the underlying resistance mechanisms. To address this issue, researchers led by Qing Deng, Ph.D., Michael Green , Ph.D., and Xubin Li, Ph.D., used single-cell RNA sequencing to establish a large dataset of CAR T cells used to treat 59 patients with R/R large B cell lymphoma. To show the utility of this dataset, the researchers used it to identify characteristics of CAR T cells among the patient population at three-month follow-up. The results showed a higher expression of genes from the glycolysis pathway in patients who achieved a complete response compared to those who did not. This single-cell atlas of CD19 CAR T cells is publicly available for further research and validation. Learn more in Cancer Cell. 

Study identifies potential target for improving treatment response in TP53-mutant AML
Patients with TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available therapies, including the combination of venetoclax and hypomethylating agents, which presents a major therapeutic challenge. A new potential therapeutic target, the epichaperome complex, is a protein network consisting of heat-shock proteins and co-chaperones found in many tumors that supports the survival of cancer cells. Researchers led by Bing Carter, Ph.D., and Michael Andreeff, M.D., Ph.D., identified high levels of epichaperomes in TP53-mutant AML cells. They found that targeting epichaperomes with the selective inhibitor PU-H71 had major anti-leukemia effects in AML cells and stem cells with TP53 mutations, but not in normal bone marrow stem cells. Importantly, they demonstrated that venetoclax selects for the outgrowth of TP53-mutant AML cells while PU-H71 eliminates these cells and enhances venetoclax activity. If confirmed in clinical trials, the concept could be an important therapeutic option for patients with TP53-mutant leukemias. Learn more in Blood.  

Targeting ryanodine receptor 2 reduces chemobrain in preclinical models
Chemotherapy-induced cognitive dysfunction, or chemobrain, is an important but poorly understood side effect of chemotherapy. One possible explanation, based on previous research, is that chemotherapy interrupts the normal function of the neuronal ryanodine receptor channel type 2 (RyR2), which regulates calcium ion signaling in neurons linked to learning and memory. In a new study, Theresa Guise, M.D., and colleagues built on previous observations that leaky RyR2 channels likely play a role not only in chemobrain, but also post-traumatic stress disorder, Alzheimer’s disease and other cognitive disorders. They demonstrated treatment with a ryanodine receptor calcium release stabilizer fixed the leaks and mitigated the overall effect of chemobrain in preclinical models, suggesting that targeting RyR2 could be a promising target in preventing chemobrain. Learn more in Science Translational Medicine.

Blood test helps identify patients at high risk of pancreatic cancer in five years  
Pancreatic cancer is projected to surge as the second leading cause of cancer-related fatalities in the United States by 2040. Still, its low incidence among the general population poses a challenge for effective screening. Recently, Johannes Fahrmann, Ph.D., Samir Hanash M.D., Ph.D., and colleagues developed a blood test that detects specific metabolites in the bloodstream, uncovering three microbial-derived metabolites and five non-microbial metabolites that are associated with increased pancreatic cancer risk. The metabolite panel, in combination with a commonly used CA19-9 marker, allowed researchers to identify individuals with high estimated absolute risk – a 13% chance – of developing pancreatic cancer within five years of blood draw. This absolute risk is about 200 times greater than the general population’s risk. These results show that the blood test can potentially identify patients who would benefit from early cancer prevention and detection strategies. Learn more in Cell Reports Medicine.

Study shows predictive value of TP53 mutations for patients with bone cancer
Patients with chondrosarcomas, the most common bone cancer, are usually diagnosed at a later age. While surgery is the primary treatment option, many patients eventually develop recurrence, highlighting a need to identify targets that could assist with risk stratification. While previous studies have highlighted the prevalence of IDH mutations in chondrosarcomas, their clinical impacts are poorly understood. To provide further insights, researchers led by Anthony Conley, M.D., and Ryan Denu, M.D., examined clinical and genomic data from 93 patients with conventional and dedifferentiated chondrosarcoma. Results showed that over 50% of patients had prevalent IDH mutations, but there was no difference in survival outcomes compared to wildtype IDH. Interestingly, TP53 mutations were present in 41.9% of patients and showed a strong association with poorer overall and metastasis-free survival, as well as a higher risk of recurrence following surgical treatment. The study emphasizes the potential of TP53 mutations for risk stratification in patients with bone cancer. Learn more in Clinical Cancer Research. 

In case you missed it
Read below to catch up on recent MD Anderson press releases.

Alejandro Aballay, PharmD, Ph.D., named Dean of MD Anderson UTHealth Houston Graduate School of Biomedical Sciences MD Anderson Research Highlights: ASTRO 2023 Special Edition  

– 30 –

END



ELSE PRESS RELEASES FROM THIS DATE:

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

2023-10-04
Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.  Now scientists have shown, in a study published today in Nature, that the small molecule works through two different mechanisms to slow tumor growth and increase survival in lab animals.  Researchers from the Tumor ...

Research shows strong link between ADHD and car crashes in older adult drivers

2023-10-04
In a study on the prevalence of attention-deficit/hyperactivity disorder (ADHD) and its association with crash risk among older adult drivers, researchers at Columbia University Mailman School of Public Health found that older adult drivers with ADHD are at a significantly elevated crash risk compared with their counterparts without ADHD. Outcomes included hard- braking events, and self-reported traffic ticket events, and vehicular crashes. Until now research on ADHD and driving safety was largely limited to ...

Pediatric RSV-associated hospitalizations before and during the pandemic

2023-10-04
About The Study: This study found that the burden of respiratory syncytial virus (RSV)-associated hospitalizations in Canadian pediatric hospitals was substantial, particularly among infants less than six months of age, and RSV hospitalizations increased in 2021-2022 compared with the pre-pandemic period, while severity of illness remained similar. These findings suggest that RSV preventive strategies for infants less than six months of age would be associated with decreased RSV disease burden in children.  Authors: Jesse Papenburg, ...

Prevalence, trends in diagnosed ADHD among children and adolescents

2023-10-04
About The Study: Based on U.S. national representative data, the estimated attention-deficit hyperactivity disorder (ADHD) prevalence was 10.08% to 10.47% among children and adolescents ages 4 to 17 from 2017 to 2022, which was similar to the prevalence from the National Health Interview Survey in 2015 to 2016 (10.20%). No significant annual change in the prevalence of ADHD was found from 2017 to 2022. Notably, the estimated prevalence of ADHD among individuals in the U.S. in this study was higher than worldwide estimates (5.3%) in earlier years (1978-2005). Authors: Wenhan Yang, M.D., Ph.D., of Guangdong ...

Effectiveness, safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease

2023-10-04
About The Study: In this post hoc secondary analysis of 10,678 participants with atherosclerotic cardiovascular disease from a randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of heart attack, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population. Authors: Mark B. Effron, M.D., of the University of Queensland-Ochsner Clinical School in New Orleans, is the corresponding ...

These robots helped understand how insects evolved two distinct strategies of flight

These robots helped understand how insects evolved two distinct strategies of flight
2023-10-04
Robots built by engineers at the University of California San Diego helped achieve a major breakthrough in understanding how insect flight evolved, described in the Oct. 4, 2023 issue of the journal Nature. The study is a result of a six-year long collaboration between roboticists at UC San Diego and biophysicists at the Georgia Institute of Technology.  The findings focus on how the two different modes of flight evolved in insects. Most insects use their brains to activate their flight muscles each wingstroke, just like we activate the muscles in our legs ...

New research finds that ancient carbon in rocks releases as much carbon dioxide as the world's volcanoes

New research finds that ancient carbon in rocks releases as much carbon dioxide as the worlds volcanoes
2023-10-04
Main points: New research has overturned the traditional view that natural rock weathering acts as a CO2 sink that removes CO2 from the atmosphere. Instead, this can also act as a large CO2 source, rivalling that of volcanoes. The results have important implications for modelling climate change scenarios but at the moment, CO2 release from rock weathering is not captured in climate modelling. Future work will focus on whether human activities may be increasing CO2 release from rock weathering, and how this could be managed. A new study led by the University of Oxford has overturned the view ...

New "Assembly Theory" unifies physics and biology to explain evolution and complexity

New Assembly Theory unifies physics and biology to explain evolution and complexity
2023-10-04
An international team of researchers has developed a new theoretical framework that bridges physics and biology to provide a unified approach for understanding how complexity and evolution emerge in nature. This new work on "Assembly Theory," published today in Nature, represents a major advance in our fundamental comprehension of biological evolution and how it is governed by the physical laws of the universe. This research builds on the team's previous work developing Assembly Theory as an empirically validated approach to life detection, ...

Unlocking the secrets of neuronal function: a universal workflow

Unlocking the secrets of neuronal function: a universal workflow
2023-10-04
Biophysically detailed neuronal models provide a unique window into the workings of individual neurons. They enable researchers to manipulate neuronal properties systematically and reversibly, something that is often impossible in real-world experiments. These in silico models have played a pivotal role in advancing our understanding of how neuronal morphology influences excitability and how specific ion currents contribute to cell function. Additionally, they have been instrumental in building neuronal circuits to simulate and study brain activity, offering ...

Munich neuroscientist receives around 1.5 million euros for research into ALS and FTD

2023-10-04
Dr. Qihui Zhou, a neuroscientist at DZNE’s Munich site, has been awarded a “Starting Grant” from the European Research Council (ERC) worth about 1.5 million euros to investigate disease mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). With her studies, which will focus on the role of immune cells in the disease process and on the most common genetic forms of ALS and FTD, Zhou aims to pave the way for better treatments. ALS and FTD are devastating diseases characterized by loss of brain cells for which there ...

LAST 30 PRESS RELEASES:

UT Health San Antonio ranks at the top 5% globally among universities for clinical medicine research

Fayetteville police positive about partnership with social workers

Optical biosensor rapidly detects monkeypox virus

New drug targets for Alzheimer’s identified from cerebrospinal fluid

Neuro-oncology experts reveal how to use AI to improve brain cancer diagnosis, monitoring, treatment

Argonne to explore novel ways to fight cancer and transform vaccine discovery with over $21 million from ARPA-H

Firefighters exposed to chemicals linked with breast cancer

Addressing the rural mental health crisis via telehealth

Standardized autism screening during pediatric well visits identified more, younger children with high likelihood for autism diagnosis

Researchers shed light on skin tone bias in breast cancer imaging

Study finds humidity diminishes daytime cooling gains in urban green spaces

Tennessee RiverLine secures $500,000 Appalachian Regional Commission Grant for river experience planning and design standards

AI tool ‘sees’ cancer gene signatures in biopsy images

Answer ALS releases world's largest ALS patient-based iPSC and bio data repository

2024 Joseph A. Johnson Award Goes to Johns Hopkins University Assistant Professor Danielle Speller

Slow editing of protein blueprints leads to cell death

Industrial air pollution triggers ice formation in clouds, reducing cloud cover and boosting snowfall

Emerging alternatives to reduce animal testing show promise

Presenting Evo – a model for decoding and designing genetic sequences

Global plastic waste set to double by 2050, but new study offers blueprint for significant reductions

Industrial snow: Factories trigger local snowfall by freezing clouds

Backyard birds learn from their new neighbors when moving house

New study in Science finds that just four global policies could eliminate more than 90% of plastic waste and 30% of linked carbon emissions by 2050

Breakthrough in capturing 'hot' CO2 from industrial exhaust

New discovery enables gene therapy for muscular dystrophies, other disorders

Anti-anxiety and hallucination-like effects of psychedelics mediated by distinct neural circuits

How do microbiomes influence the study of life?

Plant roots change their growth pattern during ‘puberty’

Study outlines key role of national and EU policy to control emissions from German hydrogen economy

Beloved Disney classics convey an idealized image of fatherhood

[Press-News.org] MD Anderson Research Highlights for October 4, 2023
Featuring progress for peripheral neuropathy and chemobrain, a CAR T cell atlas, a therapeutic target for AML, and risk prediction tools for pancreatic and bone cancer